About us
Panacea Venture is a life sciences venture fund with global vision and reach
Dedicated to creating innovation using a borderless execution model and advancing therapeutics to transform lives.
We are an accomplished team of creative thinkers, collaborators, connectors with strategic agility, cross-border expertise, and a “business development first” mindset to create value for stakeholders.
Our forward-looking and adaptive investment strategy foresees and anticipates industry and market trends, adjusting accordingly to optimize our competitive advantage.
Our firm
Panacea Venture is a life sciences venture fund with global vision and reach with unique expertise and experience in Asia, specifically in China. Spun out from Kleiner Perkins China in 2017, the founding partners built a global firm, sourcing innovation in all geographies while leveraging key advantages in select countries to benefit a company through its lifecycle using its borderless innovation model.
To date, Panacea has raised three USD funds from renowned institutional funds as well as strategic investors and has investments in more than 30 private companies and several public companies. In addition to its early-stage investments, Panacea invests in public companies and has a structured program that marries the strategic interests of biotech companies with platform technology and other innovators globally.
Our team
We listen to the market and engage with industry participants including MNC pharma that supplement our thinking about what is investible. We have a transaction “business development first” mindset to drive value and exits.
We form dynamic teams and deploy partners with relevant expertise to support portfolio company needs over the life of the company. We utilize adaptive and creative structures to maximize return.
Our strategy
With evolving market conditions, we built a strategy to invest in public companies with a strategic venture mindset. We leverage our expertise in different geographies to take advantage of unique aspects of evolving global ecosystems and country specific capital efficiencies.
Our model is asset-centric, meaning we are laser focused on programs that have strong foundational science and that can make a meaningful clinical impact; we also back promising platforms with the aim to generate differentiated assets.
We recognize the importance of multinational pharma more than ever given that they form a critical exit path for investors.